European Lead, Epidemiology, Safety and Risk Management
Dr Massoud Toussi joined IMS Health in 2011 to build its actual offer in pharmacoepidemiology and drug safety in the context of the then upcoming pharmacovigilance regulation released by the European Medicines Agency (EMA). In this role, he developed the “Epidemiology, Safety and Risk Management” activity of the company from business plan to hiring people and direct involvement in business development, bidding, designing, and conduct of post-authorization safety studies (PASS), comparative effective research (CER), drug utilization studies (DUS), surveys and systematic reviews. Currently, through a network of 18 people across Europe (the Centre of Excellence), we commercialize and implement robust multi-country studies designed and conducted to comply with the requirements of EMA, competent authorities and health technology assessment (HTA) bodies. We conduct studies based on both primary data collection, databases (claims, EMR, registries, etc) and hybrid methods. A highly connected person, Dr Massoud Toussi consider himself as a salesman of ideas, solutions and talents, acting in a highly scientific market. Dr Massoud Toussi lead a work stream in the Database special interest group in the International Society of Pharmacoepidemiology (ISPE), and represent his company in the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP), HTA Intrenational (HTAi), and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Dr Massoud Toussi also a member of the Editorial Board of the American Medical Journal.